# HORIZON-Lung: what clinicians are saying

> 50 statements from 15 sources (1 podcast, 12 posts, 2 papers), 9 of them from 3 confirmed clinicians, each linked to its source. Commentary checked Nov 21, 2026.

## Report

- Trial: Phase I/II Clinical Study of the Safety, Tolerability, Pharmacokinetics, and Efficacy of SHR-A1811 for Injection in Subjects With Advanced Non-small Cell Lung Cancer Who Have HER2 Expression , Amplification, or Mutation
- NCT ID: NCT04818333
- Registry: https://clinicaltrials.gov/study/NCT04818333
- Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- Phase: Phase 1/Phase 2
- Status: Unknown
- Drugs tested: trastuzumab rezetecan (SHR-A1811)
- Indication: advanced HER2-mutant non-small cell lung cancer
- Version: v1.0.0, edition 1
- Accepted: 2026-11-21 UTC
- Last checked: 2026-11-21 UTC
- Release hash: 6c7023d034c1451c2376fc272f3ae2892a737ad8d16de31265ef15d76e60e493

## Counts

- Commentary sources screened: 37
- Sources cited by verified statements: 15
- Verified statements: 50
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 9
- Findings: 3
- Named people in screened sources (unnamed speakers and accounts not counted): 5
- Speakers cited: 5
- Cited speakers with a verified identity: 4
- Cited clinicians, speakers with a confirmed clinical role (the abstract's clinicians): 3
- Of them physicians, whose confirmed role is a physician's, not a physician assistant's, nurse's or pharmacist's (the abstract's physicians): 3
- By role and specialty (the abstract's specialty counts):
  - 2 physician, Medical oncology
  - 1 physician, specialty not confirmed
- Organisational or shared accounts (not counted as people): 3

A verified identity says who a speaker is. A cited clinician also has a clinical role confirmed by the NPI registry or their own institution's staff page. Verified speakers without such a role, such as researchers, advocates, company staff, or clinicians whose role only a source or their own profile states, are not counted as clinicians.

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

The clinicians cited read HORIZON-Lung favorably for its tumor responses, while a physician remains undecided about its place among HER2-directed ADCs. Differing interstitial lung disease summaries are not necessarily equivalent safety measures, and the emphasis on low discontinuation does not establish negligible pulmonary risk. The separate first-line comparison with chemo-immunotherapy is mentioned without comparative outcomes, not as evidence for moving treatment earlier.

## Question clinicians left open

What do clinicians still need to see from HORIZON-Lung to define the niche for trastuzumab rezetecan (SHR-A1811) among HER2-directed ADCs in advanced HER2-mutant NSCLC after platinum-based chemotherapy and anti-PD-(L)1 treatment?

From finding F1 (7 statements from 2 speakers in 4 sources). The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. Another HER2 ADC: a clinician questions its need and place in treatment
  - 7 statements from 2 speakers in 4 sources, 1 of them a podcast or video.
  - 1 of the 2 named speakers in this finding holds this view, a confirmed clinician.
  - 1 of the report's 3 cited clinicians.
- F2. HORIZON-Lung: what speakers highlight in response rates after prior therapy
  - 16 statements from 4 speakers in 10 sources, 1 of them a podcast or video.
  - 4 of the 4 named speakers in this finding hold this view.
  - 3 of the report's 3 cited clinicians.
- F3. Responses: what speakers say
  - 9 statements from 3 speakers in 10 sources.
  - 2 of the report's 3 cited clinicians.

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding. Speakers are the named people a finding's statements cite, of any role, counted as the report counts its cited speakers; unnamed speakers and accounts are not counted.

| Finding | Statements | Passages | Sources | Speakers | Limitations |
| --- | ---: | ---: | ---: | ---: | ---: |
| F1 | 7 | 12 | 4 | 2 | 2 |
| F2 | 16 | 15 | 10 | 4 | 4 |
| F3 | 9 | 11 | 10 | 3 | 3 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Statement links to supporting passages | Statement links to context passages | Sources by kind |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- |
| F1 | 1 | 1 | 0 | 2 | 3 | 13 | 1 | 1 post or article, 1 podcast or video, 2 publications |
| F2 | 8 | 3 | 0 | 0 | 5 | 17 | 5 | 7 posts and articles, 1 podcast or video, 2 publications |
| F3 | 2 | 1 | 0 | 1 | 5 | 14 | 1 | 8 posts and articles, 2 publications |

### Trial dimensions

- Primary endpoint: Phase 1:Incidence of Adverse Events (AEs) by CTCAE v5.0 of SHR-A1811: no finding draws on it directly
- Primary endpoint: Phase 1:Severity of Adverse Events (AEs) by CTCAE v5.0 of SHR-A1811: no finding draws on it directly
- Primary endpoint: Phase1: Maximum tolerated dose (MTD): no finding draws on it directly
- Primary endpoint: Phase 1: Recommended Phase 2 dose (RP2D): no finding draws on it directly
- Primary endpoint: Phase2:ObjectiveResponse Rate (ORR): F1 (1 shared claims), F2 (4 shared claims), F3 (3 shared claims)
- Secondary endpoints: F1 (1 shared claims), F2 (3 shared claims), F3 (2 shared claims)
- Population and setting: F1 (1 shared claims), F2 (6 shared claims), F3 (3 shared claims)
- The comparison: F1 (2 shared claims), F2 (1 shared claims)
- Safety and tolerability: F2 (1 shared claims), F3 (4 shared claims)
- Design and conduct: F2 (2 shared claims), F3 (1 shared claims)

## Abbreviations

- ADC: antibody–drug conjugate
- AE: adverse event
- CNS: central nervous system
- HCP: healthcare professional
- HER2: human epidermal growth factor receptor 2
- ILD: interstitial lung disease
- MCP: Model Context Protocol, how AI agents read the report
- MTD: maximum tolerated dose
- NPI: National Provider Identifier, the US registry number for clinicians
- NSCLC: non-small cell lung cancer
- ORR: objective response rate
- RP2D: recommended phase 2 dose

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 3 | Titles free |
| Detailed analysis | 4 sections | Paid |
| Verified statements with short source quotes and links | 50 | Paid |
| Who said each statement: the cited speakers | 5 | Every edition |
| Speakers with a clinical role confirmed by the NPI registry or a staff page | 3 | Every edition |
| Speakers with verified IDs as data (NPI, ORCID, staff page) | 4 | Every edition |
| CMS-reported financial relationships (Open Payments, by company) for NPI-linked speakers | Included | Every edition |
| Trial aspects mapped | 14 | Free |
| Sources with links | 15 | Counts free |
| MCP access for your AI agent, same license key | Included | Every edition |

Every edition, the free report included, names who said each statement, as the source shows them. Each named speaker's card gives a clinical role only when the NPI registry or the person's own institution's staff page confirms it, and says which; a role only a source states is labelled as the source's. Here 3 of the 5 cited speakers have a role confirmed that way. Every edition also comes with MCP access, so your AI agent reads the same evidence with your license key, and with verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself. Social accounts are not included. The IDs are for checking attribution inside your organization. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.

## Trial aspects

10 discussed · 4 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Phase 1:Incidence of Adverse Events (AEs) by CTCAE v5.0 of SHR-A1811 | no commentary found | 0 | 0 |
| Primary endpoint: Phase 1:Severity of Adverse Events (AEs) by CTCAE v5.0 of SHR-A1811 | no commentary found | 0 | 0 |
| Primary endpoint: Phase1: Maximum tolerated dose (MTD) | no commentary found | 0 | 0 |
| Primary endpoint: Phase 1: Recommended Phase 2 dose (RP2D) | no commentary found | 0 | 0 |
| Primary endpoint: Phase2:ObjectiveResponse Rate (ORR) | discussed | 6 | 9 |
| Secondary endpoints | discussed | 5 | 8 |
| Population and setting | discussed | 8 | 11 |
| The comparison (The registered arms and what clinicians said about how they compare.) | discussed | 2 | 2 |
| Safety and tolerability | discussed | 4 | 7 |
| Design and conduct | discussed | 2 | 2 |
| Clinical niche and differentiation from other HER2-directed options | discussed | 3 | 3 |
| ADC classification and design framing | discussed | 2 | 2 |
| Related AACR25 drug commentary after chemo-immunotherapy | discussed | 1 | 1 |
| First-line phase III development beyond the reported population | discussed | 1 | 1 |

Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.

## Sources

| Channel | Statements | Cited | Screened |
| --- | ---: | ---: | ---: |
| **Video & audio · 3 statements · 6%** | | | |
| Podcasts | 3 | 1 | 1 |
| **Posts · 16 statements · 32%** | | | |
| X threads | 16 | 12 | 35 |
| LinkedIn posts | 0 | 0 | 1 |
| **Primary sources · 31 statements · 62%** (cited for context, not screened) | | | |
| Publications (primary source, cited for context) | 31 | 2 | not screened |

- Screened window: 2025-02-26 to 2026-09-11
- Cited window: 2025-02-26 to 2025-05-07
- Retrieved: 2026-11-21

Statements count each verified statement once, split evenly over the sources it cites. Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: Phase I/II Clinical Study of the Safety, Tolerability, Pharmacokinetics, and Efficacy of SHR-A1811 for Injection in Subjects With Advanced Non-small Cell Lung Cancer Who Have HER2 Expression , Amplification, or Mutation
- Registry: NCT04818333 (https://clinicaltrials.gov/study/NCT04818333)
- Study IDs: SHR-A1811-I-103
- Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- Design: Phase 1/Phase 2 · interventional, na, single group, phase1, phase2
- Status: Unknown
- Enrollment: 157 (actual)
- Start: 2021-04-23 (actual)
- Primary completion: 2025-06 (estimated)
- Primary endpoint: Phase 1:Incidence of Adverse Events (AEs) by CTCAE v5.0 of SHR-A1811 (From Day 1 to90 days after last dose ，appropriately to 3 years)
- Primary endpoint: Phase 1:Severity of Adverse Events (AEs) by CTCAE v5.0 of SHR-A1811 (From Day 1 to90 days after last dose ，appropriately to 3 years)
- Primary endpoint: Phase1: Maximum tolerated dose (MTD) (12 months)
- Primary endpoint: Phase 1: Recommended Phase 2 dose (RP2D) (12 months)
- Primary endpoint: Phase2:ObjectiveResponse Rate (ORR) (Subjects were evaluated on tumor imaging every 6 weeks after treatment initiation and every 12 weeks after 54 weeks, until imaging progression, initiation of new antitumor therapy, loss of follow-up, and death，appropriately to 3 years)
- Intervention: SHR-A1811 (drug)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- 1 clinician view in the sources used in this report is not yet captured as evidence in this edition.
- 47 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: 34 sources about other trials or topics are not included.
- Public podcast and X discussion cannot establish how common these opinions are or whether they have changed routine treatment choices.
- Repeated posts from one unnamed account and reposts do not add independent clinician opinions. Organizational summaries and relayed wording are not equivalent to individually expressed HCP assessments.
- Clinical roles are not established for several account authors. Source-described credentials or roles should not be treated as independently confirmed.
- Differing ILD percentages and response-duration descriptions are preserved as attributed. The sources do not fully reconcile their definitions or reporting time points.
- The reported clinical populations discussed here were HER2-mutant. The views do not establish benefit in HER2-overexpressing or amplified-only NSCLC, after another HER2 ADC, or in untreated or active CNS disease.
- The first-line phase III update concerns a separate study. The relevant post does not name HORIZON-Lung, and no first-line comparative outcomes are provided in that statement.
- No standalone trial protocol or exact regulatory label for SHR-A1811 was available in the sources reviewed, limiting fuller assessment of protocol details and regulatory positioning.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, edition 1, accepted 2026-11-21 UTC: current edition

Each new edition gets a new version: a new or changed finding raises the middle number (1.0.0 to 1.1.0), added evidence or newly verified speakers alone the last number (1.0.0 to 1.0.1), and a change of report format the first number. A correction fixes the published edition in place without making a new edition, so the version stays the same. Changes are corrections that add, remove or change a statement or finding, or withdraw a source; routine maintenance (people cards, names and spellings, recounts, tags and page wording) changes none. Every correction is listed here with its date. Last checked for new commentary 2026-11-21 UTC. No changes.

## Offer

- Size: Focused · 50 verified statements · 9 from 3 confirmed clinicians
- Current edition: $750. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of updates: $1,300
- 6 months of updates: $1,900
- 12 months of updates: $2,600
- Every product includes verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself (4 identity-verified speakers now); social accounts are not included. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/horizon-lung-nct04818333
- Agents: POST https://www.erudio.com/api/orders with {"report": "horizon-lung-nct04818333", "product": "edition" | "updates-3" | "updates-6" | "updates-12", "buyer_email": "...", "organization": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user and a pay_url your own payment client can pay over HTTP 402 in USDC, with MPP (on Tempo) or x402 (on Base), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=horizon-lung-nct04818333

## Cite

Erudio Health. HORIZON-Lung (NCT04818333): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 21, 2026. https://www.erudio.com/reports/horizon-lung-nct04818333

## Questions

### How much does the HORIZON-Lung report cost?

One edition costs $750 (Focused · 50 verified statements · 9 from 3 confirmed clinicians). With updates: 3 months $1,300, 6 months $1,900, 12 months $2,600. Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.

### What does the HORIZON-Lung report cover?

50 statements from 15 sources (1 podcast, 12 posts, 2 papers), 9 of them from 3 confirmed clinicians, each linked to its source. Commentary checked Nov 21, 2026. The report separates what clinicians said from what primary sources establish; it does not judge efficacy or estimate consensus.

### Can my AI agent read or buy the HORIZON-Lung report?

Yes. On https://mcp.erudio.com/free, with no sign-in, get_report_card({ "slug": "horizon-lung-nct04818333" }) previews it and create_order({ "report": "horizon-lung-nct04818333", "product": "edition", "buyer_email": "<work email>" }) orders it. Once paid, the license key reads it with read_report on https://mcp.erudio.com/mcp. [Connect your AI client](https://www.erudio.com/developers/connect)

### How current is the HORIZON-Lung report?

Edition 1 (version 1.0.0), accepted Nov 21, 2026 UTC; last checked for new commentary Nov 21, 2026 UTC. Your plan includes every new edition published during its term. We automatically check subscribed trials for new commentary every week.

## Machine access

- JSON: https://www.erudio.com/reports/horizon-lung-nct04818333.json
- Markdown: https://www.erudio.com/reports/horizon-lung-nct04818333.md
- Change feed (JSON Feed: new editions and changes): https://www.erudio.com/reports/horizon-lung-nct04818333/feed.json
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "horizon-lung-nct04818333"}`
